Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo maintenance after complete response to first-line platinum/taxane chemotherapy in ovarian epithelial or primary peritoneal cancer
2008-004429-41Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Sep 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-004429-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004429-41.